VBL Therapeutics to Present Anti-Inflammatory Properties of VBL-201 at Keystone Symposium

TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that the company will present preclinical data from its lead program, VB-201, at the Keystone Symposium on Bioactive Lipids: Biochemistry and Diseases. Eyal Breitbart, Ph.D., vice president, research at VBL is scheduled to present a poster entitled “Lecinoxoids – Novel Anti-inflammatory Oxidized Phospholipids” on Monday, June 7, 2010 at 12:30 p.m. JST in Kyoto, Japan.

MORE ON THIS TOPIC